Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer

Nature Medicine

Volumn 16, Issue 2, 2010, Pages 214-218

  Li, Yang ^a,b   Zou, Lihua ^a,c   Li, Qiyuan ^d   Haibe Kains, Benjamin ^e,f   Tian, Ruiyang ^a   Le, Yan ^a   Desmedt, Christine ^e   Sotiriou, Christos ^e   Szallasi, Zoltan ^d,g   Iglehart, J Dirk ^a,b   Richardson, Andrea L ^a,b   Wang, Zhigang Charles ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e JULES BORDET INSTITUTE   (Belgium)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; HISTONE H2AX; SMALL INTERFERING RNA;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHEMOSENSITIVITY; CHROMOSOME 8Q; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LAPTM4B GENE; LYSOSOME; MAJOR CLINICAL STUDY; MONOTHERAPY; POSTOPERATIVE CARE; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL; YWHAZ GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 8; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; MEMBRANE PROTEINS; ONCOGENE PROTEINS; RECURRENCE;

EID: 76349095348     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2090     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
2. Dowsett, M., et al. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res. 9, R81 (2007).
3. Gottesman, M.M., Fojo, T. & Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002).
4. Turton, N.J., et al. Gene expression and amplifcation in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20, 1300-1306 (2001).
5. Potti, A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12, 1294-1300 (2006).
6. Györffy, B., et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profles of drug-resistant cell lines correlates with patient survival. Oncogene 24, 7542-7551 (2005).
7. Lee, J.K., et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. USA 104, 13086-13091 (2007).
8. Liedtke, C., et al. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res. Treat. published online, doi:10.1007/s10549-009-0445-7 (15 July 2009).
9. Ingvarsson, S. Molecular genetics of breast cancer progression. Semin. Cancer Biol. 9, 277-288 (1999).
10. Albertson, D.G. Profling breast cancer by array CGH. Breast Cancer Res. Treat. 78, 289-298 (2003).
11. Albertson, D.G., Collins, C., McCormick, F. & Gray, J.W. Chromosome aberrations in solid tumors. Nat. Genet. 34, 369-376 (2003).
12. Chin, K., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541 (2006).
13. Tibshirani, R., Hastie, T., Narasimhan, B. & Chu, G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 99, 6567-6572 (2002).
14. Wang, Y., et al. Gene-expression profles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
15. Van 't Veer, L.J., et al. Gene expression profling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
16. Hu, G., et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15, 9-20 (2009).
17. van de Vijver, M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
18. Ivshina, A.V., et al. Genetic reclassifcation of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66, 10292-10301 (2006).
19. Sotiriou, C., et al. Gene expression profling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98, 262-272 (2006).
20. Pawitan, Y., et al. Gene expression profling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7, R953-R964 (2005).
21. Niemantsverdriet, M., Wagner, K., Visser, M. & Backendorf, C. Cellular functions of 14-3-3 in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 27, 1315-1319 (2007).
22. Neal, C.L., et al. 14-3-3 overexpression defnes high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 69, 3425-3432 (2009).
23. 1 phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. USA 102, 18443-18448 (2005).
24. Zweig, M.H. & Campbell, G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39, 561-577 (1993).
25. Farmer, P., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15, 68-74 (2009).
26. Silver, D.P., et al. Effcacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. (in the press).
27. Chang, J.C., et al. Gene expression profling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
28. Hogue, D.L., Kerby, L. & Ling, V. A mammalian lysosomal membrane protein confers multidrug resistance upon expression in Saccharomyces cerevisiae. J. Biol. Chem. 274, 12877-12882 (1999).
29. Matros, E., et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profles. Breast Cancer Res. Treat. 91, 179-186 (2005).
30. Lu, X., et al. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res. Treat. 108, 191-201 (2008).
31. Richardson, A.L., et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121-132 (2006).
32. Wang, Z.C., et al. Loss of heterozygosity and its correlation with expression profles in subclasses of invasive breast cancers. Cancer Res. 64, 64-71 (2004).
33. Desmedt, C., et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158-5165 (2008).
34. Harrell, F.E. Jr., Califf, R.M., Pryor, D.B., Lee, K.L. & Rosati, R.A. Evaluating the yield of medical tests. J. Am. Med. Assoc. 247, 2543-2546 (1982).
35. Pencina, M.J. & D'Agostino, R.B. Overall C as a measure of discrimination in survival analysis: model specifc population value and confdence interval estimation. Stat. Med. 23, 2109-2123 (2004).
36. van Vliet, M.H., et al. Pooling breast cancer datasets has a synergetic effect on classifcation performance and improves signature stability. BMC Genomics 9, 375 (2008).